Trial Profile
A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cosibelimab (Primary) ; Ublituximab (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 19 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 20 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2021 Study design changed from single group assignment to parallel. Cohort B and C added with Ublituximab and Bendamustine.